Monday Scaries! Proposed revisions to the Office of Management and Budget (OMB) Uniform Guidance could fundamentally alter how rad research is funded, shared, and sustained. As of this morning, nearly 99,000 comments have been filed, reiterating the real-world impact these rules would have on clinical trials, trainee development, as well as patient care.
- Conference Restrictions—Federal agencies would need to expressly approve conference attendance at the time of the award (often years before results exist, of course).
- Pub Costs—Article processing charges (APCs) and open-access fees would become “presumptively unallowable,” creating a conflict with federal public-access mandates.
- Award Instability—New authority would allow agencies to terminate awards “at will” or based on shifting political priorities, potentially stranding patients in longitudinal imaging trials.
- Admin Delays—Mandatory pre-issuance reviews by political appointees could delay the procurement of specialized imaging equipment and the start of clinical studies.
Submit your comment by this coming MONDAY, JULY 13th.
Pro Tips: You may comment anonymously. Consider leveraging the OMB Rule Comment Assistant or the FASEB Defend Research tool to generate your template.
- Be Specific—Choose up to 3 provisions that will impact you most significantly. Personal examples of how these rules would delay a trial or harm those in training are more effective than general complaints.
- Congressional CC—Copy your comments electronically to your own member of Congress. Help them understand how these regulatory changes affect their constituents and local research infrastructure.
RadFYI: Taken together, these OMB provisions create an environment of front-end delays and mid-project instability—the exact opposite of what is needed for imaging innovation.
Leave a Reply